Abstract 3919
Background
The characterization of the adaptive immune landscape in epithelial ovarian cancer (EOC) is of paramount importance for the stratification of patients (pts) for therapeutic interventions, especially in the context of immunotherapy.
Methods
In the present analysis pts with EOC and available tumor tissue were included. All pts had received treatment with platinum and paclitaxel.We evaluated elements of the adaptive immunity such as Tertiary Lymphoid Structures (TLS), plasma cells (PCs) and CD8+T cells, intraepithelial (iCD8) and stromal (sCD8), as well as p53 immunoexpression. Assessment of TLS (presence, absence) and PCs (4-tiered score) was performed in H&E stained whole tumor sections whereas of CD8 and p53 in IHC stained Tissue Microarrays (TMAs), constructed from the same tumor area. For iCD8, 5 cells/HPF was considered as the cut-off value for low vs high expression, whereas absolute absence of p53 expression or immunopositivity in > 60% of tumor cells was considered as p53 mutated by IHC (mIHCp53). Survival data have been retrieved from 613 patients.
Results
From 04/1996 to 11/2016 687 pts were treated; median age was 58.8 years (range 21.7-84.4). Stage III disease was diagnosed in 431 (69.3%), while stage IV in 70 (11.3%) pts. Most tumors had absence of TLS (74.2%), 0-1 PCs score (78.7%), low iCD8 and sCD8 expression (75.4% and 50.3%) and mIHCp53 (73.6%). The presence of TLS correlated with high iCD8 and sCD8 expression and 2-3 PCs score (all p’s <0.001), but not with prognosis in this cohort (p = 0.99). The median OS was 71.9 months (95% CI 65.5-83.9). Age was an independent unfavorable prognosticator for OS (HR = 1.02, p < 0.001). Low iCD8 expression and mIHCp53 univariately conferred higher risk of death (HR = 1.42; p = 0.038 and HR = 1.54; p = 0.010, respectively). Upon multivariate analysis, low iCD8 expression retained its unfavorable prognostic significance for OS (HR = 1.54, p = 0.011), while a trend towards worse survival was detected for mIHCp53 (HR = 1.38, p = 0.062).
Conclusions
The presence of effector cells of adaptive immunity such as PCs and cytotoxic T cells correlated with the presence of TLS and was closely linked to clinical outcome in EOC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hellenic Cooperative Oncology Group (HeCOG).
Funding
Hellenic Cooperative Oncology Group (HeCOG).
Disclosure
E. Fountzilas: Shareholder / Stockholder / Stock options: Deciphera; Travel / Accommodation / Expenses: K.A.M Oncology / Hematology; Travel / Accommodation / Expenses: Merck. G. Pentheroudakis: Advisory / Consultancy, Leadership role, Research grant / Funding (institution): Amgen; Advisory / Consultancy, Leadership role, Research grant / Funding (institution): Merck; Advisory / Consultancy, Leadership role, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Leadership role, Research grant / Funding (institution): Roche; Advisory / Consultancy, Leadership role: Bristol-Myers Squibb; Advisory / Consultancy: MSD; Advisory / Consultancy, Leadership role, Research grant / Funding (institution): Lilly; Leadership role, Research grant / Funding (institution): Boehringer; Leadership role: Enorasis. G. Aravantinos: Advisory / Consultancy: Novartis; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Roche Hellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Amgen; Advisory / Consultancy: Genesis Pharma; Advisory / Consultancy: Merck; Advisory / Consultancy: Pfizer. G. Fountzilas: Advisory / Consultancy: Pfizer; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Roche; Honoraria (self): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
3006 - Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study.
Presenter: Violaine Randrian
Session: Poster Display session 2
Resources:
Abstract
3697 - The expression of Versican and its role in pancreatic neuroendocrine tumor
Presenter: Zhao Sun
Session: Poster Display session 2
Resources:
Abstract
6073 - Characteristics of patients with thyroid carcinoma in the united states
Presenter: Dina El-Habashy
Session: Poster Display session 2
Resources:
Abstract
2124 - The discrimination of pituitary adenomas and craniopharyngioma on MRI: from image features to texture features
Presenter: Hanyue Xu
Session: Poster Display session 2
Resources:
Abstract
3786 - Proportion of Peripheral Lymphocyte Subsets Correlates with the Progression-free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumor Patients
Presenter: Yitao Gong
Session: Poster Display session 2
Resources:
Abstract
2263 - Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma
Presenter: Enas Elkhouly
Session: Poster Display session 2
Resources:
Abstract
4386 - SILVELUL Project: Immunohistochemical panel analyses as potential predictive and prognostic factors in Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus
Presenter: Ana De Jesus-Acosta
Session: Poster Display session 2
Resources:
Abstract
2302 - Carcinoid heart disease (CHD): the CRUSOE-NETs, a prospective cohort study from the French Group of Endocrine Tumors (GTE)
Presenter: Kathleen Dekeister Geoffroy
Session: Poster Display session 2
Resources:
Abstract
5749 - Safety of high doses of somatostatin analogs in well differentiated NENs in elderly
Presenter: Massimiliano Cani
Session: Poster Display session 2
Resources:
Abstract
3931 - Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumors (NETs).
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract